Key Highlights

• XLV Best Monthly Performance in Years: The healthcare ETF posted its strongest monthly performance in years as capital shifted from tech into biotech.

• Candel Therapeutics Benefits From Rotation: The pivotal Phase 3 AURORA trial initiation coincided with the broader sector rotation tailwind.

• Sarepta Therapeutics Also Gains: FDA acceptance of Duchenne treatment applications added company-specific catalyst on top of sector rotation.

A broader healthcare sector rotation took hold in late June 2026, with the XLV healthcare ETF posting its best monthly performance in years as investors shifted capital from richly valued tech names into defensive and biotech stocks.

This rotation reflects a broader reassessment of relative valuations across sectors, as investors who had concentrated capital in technology names amid the AI infrastructure boom began seeking diversification into healthcare and biotech companies with more attractive risk-reward profiles.

Candel Therapeutics (NASDAQ: CADL) and Sarepta Therapeutics (NASDAQ: SRPT) both benefited from this rotation alongside positive company-specific clinical catalysts, illustrating how sector rotation and individual stock news can compound to drive outsized moves when timed together.

Candel's initiation of its pivotal Phase 3 AURORA trial and Sarepta's FDA acceptance of supplemental Duchenne treatment applications both represented genuine company-specific positive developments that coincided favorably with the broader sector-level capital rotation into healthcare.

This pattern of sector rotation amplifying individual stock catalysts illustrates an important dynamic for investors to recognize: the same fundamental news can produce significantly different magnitude stock reactions depending on the broader sector-level capital flow environment at the time of the announcement.

()